Qiuxia Chen

Biochemical, biophysical and cellular assay • Establish and optimize assays for targets in radioligand therapy. • Lead in vitro biology team. Project management for radiopharmaceutical development • Conduct background research on potential drug targets. • Lead project, define scope and go/no-go decision points. • Organize internal resources and coordinate with CROs, ensure that all projects are on-schedule.

Biochemical, biophysical and cellular assay • Establish and optimize assay protocols for novel targets. • Small molecule evaluation and MOA study. DNA encoded library (DEL) screening • DEL selection of different targets • DEL selection optimization and innovation Project management • Manage DEL screening projects, design experiment plan. • Organize and coordinate internal resources, ensure that all projects are delivered on-time. • Manage the relationship with the client.

Department of Biochemistry and Molecular Medicine 07/2013-03/2015: High-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications • developed a novel strategy to achieve consistent high-yield biosynthesis of chimeric RNAs carrying various small RNAs (miRNAs, siRNAs and RNA aptamers) • performed deep RNA sequencing analyses and revealed that mature miR-124 and target GFP-siRNA were selectively released from chimeric RNAs in human cells. • miR-124, GFP-siRNA and malachite green aptamer released from chimeric RNAs were proved functional in either cell or animal study. • developed a specific and label-free method to determine serum RNase activities in pancreatic cancer patients. 07/2013-09/2014: Recombinant human pre-miRNA-34a as novel cancer therapeutics • biosynthesis of human pre-miRNA-34a agents in Escherichia coli. • rapid purification of recombinant RNA using FPLC. • suppression of cell proliferation and xenograft tumors growth in animal models by pre-miRNA-34a. 07/2013-04/2014: hsa-miR-1291 function Study • tested the expression of hsa-miR-1291in different cell lines by qRT-PCR. • constructed UTR reporter plasmids, performed luciferase assay and western blot to determine the target of hsa-miR-1291.

Evaluation of cationic polylactide(CPLA) as carriers for gene delivery • tested transfection efficiency of CPLA54 by using different weight ratios of the PhrGFP II-1/CPLA54 complex. • determined toxicity of CPLA54 in different cell lines. • investigated the capacity of CPLA54 as a nanocarrier for micrRNA expression in comparison to lipofectamine2000.

Pharmaceutical Analysis, College of Pharmaceutical Sciences 09/2011-10/2012:Mechanism involded in P-gp(MDR1) induction by vinblastine • established vinblastine resistant Caco-2 cells. • assayed AP-1 and NF-kB luciferase activity in vinblastine resistant and wild type Caco-2 cells. • tested the inhibition of MDR-1mRNA expression by c-jun and NF-kB inhibitors. 07/2010-07/2011:Establishment of LLC-PK1 Cell Line Expressing P-gp 03/2010-06/2010:Establishment of MDCK-MDR1 Cell Line Expressing CYP3A4

West China School of Pharmacy